Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
Proficio Capital Partners LLC massively increased its stake in Amgen, acquiring 470,808 shares in Q4. This move significantly ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
17h
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
Hosted on MSN1d
Tezspire Treats Chronic Sinus Symptoms With Nasal PolypsTezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...
Gulf International Bank UK Ltd reduced its stake in Amgen by 2.5%, selling 1,041 shares in Q4. Several other institutional ...
Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...
Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a ...
We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...
We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback